SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that neocloud financing is tightening and many providers may fail or consolidate has fueled concern about NBIS and selling across the sector. Bears point to debt and execution risks, while bulls argue Nebius is better positioned because it secured Citi financing and has substantial customer commitments.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Elon Musks warning that neoclouds could face failures and consolidation, alongside concerns about tighter financing for debt-heavy AI data-center expansion, is weighing on IREN and its peers. Traders disagree over whether IRENs contracts, power capacity and funding distinguish it from weaker operators or whether sector-wide capital risks threaten its growth; some also view Musks comments as self-serving criticism of competitors.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 personalized melanoma-vaccine results with Merck are driving attention: the data were viewed as clinically positive, but the stock sold off as traders questioned whether they met high expectations after a steep rally. Bulls see validation for a broader cancer-vaccine platform, while bears focus on valuation and the uncertain path to commercial adoption.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils presidential election result and concerns about fiscal policy and market uncertainty are driving a broad selloff in Brazilian equities, including NU. Traders are divided between viewing the drop as a buying opportunity and waiting for the political and economic risks to become clearer.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is in focus after Lula da Silvas runoff victory triggered a sharp selloff in Brazilian assets, as traders reassess the countrys fiscal and economic outlook and the real. The community is split between viewing the drop as an overreaction and potential buying opportunity and expecting further weakness amid political uncertainty.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory has pressured Brazilian equities as traders weigh political and fiscal uncertainty for state-controlled Petrobras. PBR traders are split between viewing the selloff as a buying opportunity, citing the companys oil business and dividends, and reducing exposure amid concerns about the political outlook.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb to a 52-week high and around the $30 level is driving discussion, with bullish traders celebrating a potential breakout and others flagging resistance and concerns about the companys growth outlook. Some cite recent oncology and pipeline updates, while many frame the move as a technical recovery ahead of earnings rather than a single confirmed catalyst.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

Brazilian election results and uncertainty over the countrys policy direction are driving attention to XP alongside other Brazilian stocks. Traders have debated whether the political shock warrants further selling or a rebound, with some seeing a more business-friendly balance of power as supportive for Brazilian equities.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibres latest quarterly results are driving discussion: revenue and EPS beat expectations, but shares fell as investors focused on lower profits and margin compression amid heavy investment in logistics, shipping, and credit. Traders are split between viewing the pullback as a buying opportunity given the companys growth and worrying that profitability and the stocks weak performance may remain under pressure.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas steep selloff and fresh lows dominate the discussion, with traders focused on uncertainty around a potential Monee listing and Sea Cloud launch, as well as insider sales and concerns about spending and competition. Bears see added uncertainty for shareholders, while some investors argue Seas growth and Monees value are being discounted and the stock looks oversold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on top names. See analyst rating changes for PepsiCo, Octave Intelligence, Fervo Energy, Avalo Therapeutics, and Keurig Dr Pepper.read more...

Biotech Stocks To Add to Your Watchlist - May 6th

Danaher, Avalo Therapeutics, Vertex Pharmaceuticals, United Therapeutics, argenex, ImmunityBio, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science and technology t...

Avalo Therapeutics (NASDAQ:AVTX) Reaches New 1-Year High Following Analyst Upgrade

Avalo Therapeutics (NASDAQ:AVTX) Sets New 52-Week High Following Analyst Upgrade...

Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $58.00

BTIG Research upped their target price on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a 'buy' rating in a research report on Wednesday...

This Small-Cap Biotech Stock Is Tracking A Crucial Bullish Technical Milestone – And Retail Traders Are Taking Notice

Equity

Avalo Therapeutics announced a $375 million capital raise following a positive Phase 2 trial for skin inflammation treatment.

Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why

Avalo Therapeutics Inc. rises sharply in pre-market trading following a Phase 2 trial win and a $375 million offering.read more...

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results 

Avalo was evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa across two dosing regimens.


Avalo Therapeutics (AVTX) to Release Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-avalo-therapeutics-inc-stock...

Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,457 shares of the company's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the...

Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Avalo is looking to sell 19.73 million shares at $17.75 each, a 9% premium over Tuesday’s closing price.</li><li>Avalo plans to use the proceeds, alongside existing cash reserves, to advance development of Abdakibart, its skin inflammation treatment.</li><li>On Tuesday, Avalo said its Phase 2 trial of Abdakibart met its primary endpoint.</li></ul>Shares of Avalo Therapeutics (AVTX) skyrocketed nearly 45% in pre-market trading on Wednesday, as investors cheered the biotech firm’s latest data from a Phase 2 trial to treat a type of skin inflammation, as well as a capital raise to support its pipeline.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AVTX">AVTX shares</a> would trade at their highest levels in more than two years, while also breaching the key 50-day moving average (50-DMA) for the first time in nearly a month.<h2 class="st-heading-2">Offering Priced At A Premium Over AVTX Stock’s Tuesday Closing Price</h2>Avalo Therapeutics is expected to raise around $375 million via a public offering, selling 19.73 million shares at $17.75 each, along with pre-funded warrants for 1.4 million shares priced at a similar level. This represents a 9% premium over the stock’s closing price on Tuesday.The company also granted underwriters a 30-day option to purchase up to an additional 3.17 million shares on the same terms. The deal is set to close on May 7, 2026.Avalo plans to use the proceeds, alongside existing cash reserves, to advance development of Abdakibart, including an upcoming Phase 3 data readout. Remaining funds will support working capital and general corporate needs.<h2 class="st-heading-2">AVTX’s Treatment Meets Primary Endpoint In Phase 2 Study</h2>On Tuesday, Avalo <a href="https://stocktwits.com/news-articles/markets/equity/avtx-surges-after-hours-as-skin-disease-drug-shows-desired-clinical-results/cZQDXbORe9U">reported</a> strong Phase 2 results from its Lotus trial of Abdakibart, an investigational treatment for patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin condition.The study met its primary endpoint, with 75% reductions observed in 42.2% of patients on the 150 mg dose and 42.9% on the 300 mg dose at Week 16, both statistically significant and among the highest reductions reported in similar trials.Abdakibart was well tolerated, with mostly mild to moderate side effects and no unexpected safety issues. Based on these results, Avalo plans to advance the treatment into Phase 3 development.<h2 class="st-heading-2">Retail Pegs $21 As AVTX’s Support</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes on the counter surged 5,900% over a 24-hour period.Chatter focused on the offering, with one user saying the stock could fall from its current levels and settle at $21.<stembedurl>https://stocktwits.com/Alternative1/message/652405013</stembedurl>Another user also saw $21 as a key level, adding that despite the strong fundamentals, the stock price won’t climb to $30 on Wednesday.<stembedurl>https://stocktwits.com/Alternative1/message/652397421</stembedurl>AVTX shares have declined 11% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of stock market chart on a glowing particle world map. (Representative Image: Getty Images)

Why Did AVTX Stock Surge 45% In Pre-Market Today?

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.93
Prev Close	$7.45
Open	$7.27
Dividend Yield	0.00%
50-Day Moving Average	$16.06
Beta	1.15
Avg. Volume	1.16M
PE Ratio	-1.46

52-Week High	$24.27
52-Week Low	$6.53
Market Capitalization	$371.66M
EPS (Annual)	-$5.84
Price to Book	0.82
Revenue Per Employee	$1,787.88

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVTX Fundamentals